Skip to:

News

Official news and announcements about our company and our products.


A new apoD citation in our data base

Herzig et al. have analyzed plasma apoD with our ELISA. The authors have made an interesting study showing that physical activity per se and not loss in body weight attenuated several circulating lipoprotein lipids in sedentary overweight subjects. This means that physical activity already at a low activity level could have long term prevention effects on cardio-metabolic diseases.

Great news, you don’t have to run a marathon, just start walking!

Thursday, September 28, 2017

Live cells after FluoroSpot assay enable plasticity studies

Abhishek Das and colleagues take advantage of the (underappreciated) fact that cells are alive and well after a FluoroSpot assay. By a clever single-cell sorting procedure of T cells onto an IFN-gamma/IL-8 FluoroSpot plate, the authors were able to first confirm that recent thymic emigrants produce only IL-8 and not IFN-gamma, and then – by removing the still alive cells with a pipette and transferring them to another plate for cloning – show that the very same cells transitioned into IFN-gamma producing Th1 cells.

The IFN-gamma/IL-8 FluoroSpot kit was customized for this particular project. FluoroSpot customizations may presently be developed upon request.

Tuesday, September 26, 2017

First external reference for our neutralizing anti-IL-21 mAbs

This recent paper by You et al 2017 demonstrates the utility of our unique antibody mixture MT216G/21.3m. By blocking the IL-21 activity of Th9 cells from breast cancer patients, the authors showed that CD8+ T cell-mediated tumor killing is dependent on IL-21 (and IL-9) from Th9 cells.

 

For further information on the anti-IL21 monoclonal antibody mixture, please go here.

Monday, September 25, 2017

The first Cotton Rat IFN-γ ELISpot kit launched!

Cotton rats are an important animal model due to its high susceptibility to certain human pathogens.

Mabtech’s newly developed monoclonal antibodies offer sensitive quantification of cotton rat IFN-γ using ELISA and our ELISpot kits are ideal for enumeration of IFN-γ secreting cells.

Find out more about the Cotton rat IFN-γ assays here and find available products in the web shop.

Thursday, September 21, 2017

Summer’s harvest now in the Citations Database

We just increased the size of our Citations Database with more than 100 recently published scientific papers. Among them, the two Nature articles mentioned below (Sahin et al and Ott et al) as well a paper where our biotinylated anti-human insulin mAb is utilized with great success (Xu et al).

Fun (present) facts:

Total number of papers: 1391

Number of papers regarding cow samples: 38

Number of papers including ELISpot assays: 846

Number of papers by a first author named Zhang: 11

Monday, August 28, 2017

Yet another successful cancer vaccine trial

In a Nature Letters article published in July 2017, a group from the Dana-Farber Cancer Institute led by Catherine Wu reported an exciting proof-of-principle study showing that a personal neoantigen vaccine is safe, strongly immunogenic, and capable of inducing tumor-reactive T cells.

Ott et al. Nature Letters 2017 used whole-exome sequencing of DNA from matched tumor and normal cells to identify somatic mutations and used HLA binding prediction algorithms to create personalized HLA-binding peptide sequences. Corresponding peptides were synthesized and used as immunogens administered with poly-ICLC in patients with previously untreated high-risk melanoma in a phase I study.

In conjunction with flow cytometry, the authors used Mabtech IFN-γ ELISpot assays to show that personalized neoantigen vaccines generate polyfunctional CD4- as well as CD8-specific T cell responses that persisted over time. They also showed that subsequent checkpoint blockade therapy (anti-PD1 mAb pembrolizumab) broadens the repertoire of neoAg-spec T cells. This study demonstrates that neoantigen vaccines could address the heterogeneity of tumors and minimize escape, and further suggests that synergy may be achieved with checkpoint blockage and other immunotherapeutics.

Tuesday, August 22, 2017

Great news for RNA-based cancer vaccines

Very nice data from Sahin et al (Nature, 2017), showing that neo-epitope vaccination works in human subjects with melanoma.

The authors sequenced RNA from tumor biopsies to identify mutations that could serve as HLA-binding neo-epitopes. The resulting RNA-based vaccines were subsequently injected into a lymph node of the patient, and the idea is that dendritic cells will engulf the vaccine, translate the RNA-encoded antigens and present them to T cells.

The immunogenicity of the mutations was analysed by IFN-γ ELISpot pre- as well as post-vaccination. The promising post-vaccination results suggest that these kinds of patient-tailored vaccines may prevent recurrent disease in high risk patients, especially in combination with check-point blockade.

A very interesting bonus-finding was that a single mutation may give rise to neo-epitopes presented on different HLA class I molecules to different CD8+ T cell clones.

To find other references for Mabtech’s human IFN-γ ELISpot kits, please visit our Citations Database.

Friday, July 7, 2017

Launch of Bovine IgG ELISpot

With our new Bovine IgG ELISpot kit, you will be able to quantify the number of antibody producing plasma cells from cow. Antibodies are available as separate reagents.

The new kit and antibodies can be found in our webshop.

Thursday, July 6, 2017

Finally an ELISAPRO for Human TNF-ɑ

Human TNF-ɑ ELISAPRO kits for sensitive quantification of TNF-ɑ in serum, plasma and cell culture supernatants are now available in the web shop.

Our ELISAPRO kits are carefully validated complete kits including pre-coated strip-plates, reagents and buffers.

Thursday, July 6, 2017

Re-launch of mAb pair for llama IFN-γ

We are re-introducing the antibody clones PAN and bIFNγ-I after having confirmed good reactivity with llama IFN-γ.

The antibodies are available as separate reagents now, and complete ELISA and ELISpot kits will follow. 

Monday, July 3, 2017